CENTRAL ASIAN GASTROENTEROLOGY WEEK 2015
Almaty, September 30 - October 3, 2015
Atakent Park Hotel, Timiryazev Str. 42, Almaty, 050057, Kazakhstan
PRELIMINARY PROGRAM
Date/time
30.09.2015
08.00-09.00
09.00-09.15
09.15-09.30
09.30-11.00
11.00-11.30
11.30-13.00
13.00-14.00
14.00-16.00
16.00-16.30
16.30-18.00
18.00-19.00
01.10.2015
08.00-09.00
09.00-11.00
11.00-11.30
11.30-13.00
Sessions
Registration
Welcome messages
Initiatives of EASL in hepatology
Plenary session: Managerial issues of the medical care in field of gastroenterology and
hepatology in Central Asia
Coffee break
Session 1: Hepatitis C
Session 2: Gastroesophageal reflux disease
 Current interferon-containing regimens
 GERD &NERD
and their optimization
 Extraesophageal manifestations
 Triple therapy in today’s practice
 Management of dysplasia in Barrett’s
esophagus
 DAA-based treatment: The real world
experience
 Panel discussion
 Panel discussion
Lunch
Session 1: Hepatitis C (cont)
Session 3: Hp associated injuries
 Current and future interferon-free
 Old problem and current approaches
regimens
 Risks and benefits of PPIs
 Treatment of hepatitis C in difficult-to Management of patients on antitreat patient groups
thrombotic agents
 Treatment of hepatitis C in special
 Panel discussion
populations
 Panel discussion
Coffee break
Session 4: Hepatitis B and D
Session 5: Functional dyspepsia
 Current standards and prospective
 Functional GI-disorders. Definitions and
therapy of hepatitis B
classification
 Viral hepatitis B and pregnancy
 Management of motility disorders
 Hepatitis B reactivation
 Prokinetics or/and PPIs in functional GIdisorders
 Management of chronic hepatitis D
 Panel discussion
 Panel discussion
Internal meeting of the principal regional experts in gastroenterology, hepatology and
infectious diseases
Registration
Session 6: Non alcoholic fatty liver disease
 Insulin resistance, lipid metabolism and
Inflammatory driven adipose tissue
dysfunction in NAFLD
 Diagnosing and management
NAFLD/NASH today
 Anti-oxidants in NASH
 Panel discussion
Coffee break
Session 8: Alcoholic liver disease and Drug
induced liver injury
 Universal mechanisms of liver injury
 Management of alcoholic liver disease: an
update
 Drug induced liver injury: different types
Session 7: Inflammatory bowel diseases
 The current concept for the etiology of
Crohn’s disease and ulcerative colitis
 Small bowel evaluation in Crohn’s disease
 Perianal fistulas in Crohn’s disease
 Panel discussion
Session 7: Inflammatory bowel diseases
(cont)
 The efficacy and safety of immune
suppressive therapy in IBD
 Medical and surgical treatment options
 New biological agents – new possibilities
13.00-14.00
14.00-16.00
16.00-16.30
16.30-18.00
02.10.2015
08.00-09.00
09.00-11.00
11.00-11.30
11.30-13.00
13.00-14.00
14.00-16.00
and differential approach
 Panel discussion
Lunch
Session 9: Autoimmune and cholestatic liver
diseases
 Autoimmune hepatitis: current and
investigational therapy
 Primary biliary cirrhosis and primary
sclerosing cholangitis: are there any
news?
 IgG4-associated cholangitis: do not miss
the diagnosis
 Cholestatic conditions in pregnancy:
differential diagnosis and practical
approach
Panel discussion
Coffee break
Session 11: Pediatric hepatology
 Chronic hepatitis B and C in children: who
does really need therapy
 Wilson's disease: an update
 Extrahepatic portal hypertension in
pediatric populationPanel discussion
Registration
Session 13: Liver cirrhosis and its
complications
 Management of ascites and hepatorenal
syndrome
 SPB and other infections in cirrhotic
patients: early diagnosis and treatment
 Gastrointestinal bleedings in cirrhotic
patients: cause, algorithm of therapy and
prophylaxis
 Hepatic and portal vein thrombosis
 Hepatic encephalopathy: diagnostic tools
and treatment options
 Panel discussion
Coffee break
Session 15: Hepatocellular carcinoma
 Recommendations for HCC screening
 Diagnostics for HCC and role of tumor
biopsy
 Current and promising management of
HCC
 Panel discussion
Lunch
Session 17: Liver transplantation
 Liver transplantation in end stage liver
disease
 Liver transplantation in HCC: Are Milan
criteria still important?
 Antiviral prophylaxis and antiviral therapy
in the context of liver transplantation
 Case presentations
 Panel discussion

in the treatment of IBD
Panel discussion
Session 10: Biliary disorders. Acute and
chronic pancreatitis
 Recommended approaches in
cholelithiasis
 Post-operative biliary disorders
 Awareness about proper diagnosis and
treatment of chronic pancreatitis
 Best strategies for chronic pancreatitis
management
 Panel discussion
Session 12: Pediatric gastroenterology
 Practical tips for the diagnosis and
management of celiac disease
 IBD in children and adolescents
 Enteral nutrition in pediatric GI
 Panel discussion
Session 14: Gut microbiota, infectious and
parasitic gastrointestinal diseases
 Current concept of gut microbiota and
probiotics use
 Gut-liver axis in relation to NASH
 C. difficile colitis in clinical practice: do not
miss the diagnosis
 Infectious diarrhea
 Parasitic gastrointestinal diseases
 Panel discussion
Session 16: Malignant tumors of
gastrointestinal tract
 Current recommendations for screening
and surveillance of colorectal cancer
 Endoscopic diagnosis and management of
pancreatic cancer
 Tumor imaging in gastroenterology
 Panel discussion
Session 18: Modern technologies in
gastrointestinal surgery
 Endoscopic mucosal resection: pros and
cons
 New treatment options for IBD

Endoscopic and surgical interventions in
pancreatitis cysts
 Case presentations
 Panel discussion
16.00-16.30
16.30-18.00
Coffee break
Plenary session: Closing remarks
03.10.2015
08.00-09.00
09.00-13.00
13.00-14.00
14.00-16.00
Registration
Master class 1: Endoscopy course
Lunch
Master class 2: Endoscopic ultrasonography
Suggested faculty:
Prof. Markus Peck-Radosavljevic, Austria
Prof. Graham Foster, UK
Dr. Holger Hinrichsen, Germany
Prof. Michael Manns, Germany
Prof. Cihan Yurdaydin, Turkey
Prof. Victor de Leidinghen, France
Prof. Matthias Loehr, Sweden
Prof. Jose Mato, Spain
Prof. Christopher Probert, UK
Prof. Hiroshi Yatsuhashi, Japan
Prof. Susumi Eguchi, Japan
Dr. Atsumasa Komori, Japan
Dr. Wojciech G. Polak, Netherlands
Dr. Asa’d Izziddin Dajani, Saudi Arabia
Dr. Franco Scaldaferri, Italy
Prof. Marina Mayevskaya, Russia
Prof. Igor Bakulin, Russia
Dr. Kulpash Kaliaskarova, Astana, Kazakhstan
Prof. Alexander V. Nersesov, Almaty, Kazakhstan
Suggested sponsors:
Abbott
Abbvee
Bayer
Berlin-Chemie
Biocad
Delta Medical
GlaxoSmithKline
Gilead
Ferring
Janssen
MSD
Novartis
Olympus
Pro.Med.Cs.Praha.a.s.
Roche
Sanofi
Storz
SUN Pharma
Takeda
Yumgiskor